← All trials
NCT05864144
Phase 1/Phase 2Interventional
Trials that are a combination of phases 1 and 2.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 31, 2023
- Primary completion
- Jun 30, 2027
- Completion date
- Jun 30, 2027
- First posted
- May 18, 2023
- Last posted
- Sep 13, 2023
- Enrollment
- 129
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sensei Pharmaceuticals, Inc.Lead sponsor
- RegeneronCollaborator
- Sensei Pharmaceuticals, Inc.Study director
Drugs studied
Indications studied
- Urinary Bladder Neoplasms
- Breast Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Uterine Cervical Neoplasms
- Colonic Neoplasms
- Esophageal Neoplasms
- Head and Neck Neoplasms
- Kidney Neoplasms
- Melanoma
- Neoplasms
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Prostatic Neoplasms
- Sarcoma
- Stomach Neoplasms
- Thyroid Neoplasms
- Uterine Neoplasms
- Carcinoma, Merkel Cell
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.